Related references
Note: Only part of the references are listed.High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy
Edmund K. Bartlett et al.
CANCER (2020)
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Allison Betof Warner et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas
Lichen Jing et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development
Shira Tabachnick-Cherny et al.
MOLECULAR CARCINOGENESIS (2020)
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
Praful Ravi et al.
JAMA ONCOLOGY (2020)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M. Kluger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P. D'Angelo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO plus IPI) or NIVO alone
C. Robert et al.
ANNALS OF ONCOLOGY (2020)
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153
David M. Waterhouse et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
Siddharth Sheth et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases
R. Knackstedt et al.
ANNALS OF ONCOLOGY (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
Jaclyn LoPiccolo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Todd C. Knepper et al.
CLINICAL CANCER RESEARCH (2019)
Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer
Tsukasa Hasegawa et al.
ANTICANCER RESEARCH (2019)
Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Shailender Bhatia et al.
CLINICAL CANCER RESEARCH (2019)
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors
Malaka Ameratunga et al.
EUROPEAN JOURNAL OF CANCER (2018)
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics
Kelly G. Paulson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Aly-Khan A. Lalani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection
Ata S. Moshiri et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy
Maria L. Ascierto et al.
CLINICAL CANCER RESEARCH (2017)
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
Gerald Goh et al.
ONCOTARGET (2016)
Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System
Kelly L. Harms et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: A retrospective study
Julia Zaragoza et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
Jayasri G. Iyer et al.
CANCER MEDICINE (2016)
The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma
Paul William Harms et al.
CANCER RESEARCH (2015)
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas
Stephen Q. Wong et al.
CANCER RESEARCH (2015)
Risk of Merkel Cell Carcinoma After Solid Organ Transplantation
Christina A. Clarke et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Risk of Merkel Cell Carcinoma After Solid Organ Transplantation
Christina A. Clarke et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
The Emerging Role of Neutrophil to Lymphocyte Ratio in Determining Colorectal Cancer Treatment Outcomes: A Systematic Review and Meta-Analysis
George Malietzis et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
Olga K. Afanasiev et al.
CLINICAL CANCER RESEARCH (2013)
Emerging and Mechanism-Based Therapies for Recurrent or Metastatic Merkel Cell Carcinoma
Natalie J. Miller et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2013)
PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
Evan J. Lipson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Antibodies to Merkel Cell Polyomavirus T Antigen Oncoproteins Reflect Tumor Burden in Merkel Cell Carcinoma Patients
Kelly G. Paulson et al.
CANCER RESEARCH (2010)
Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma
V. Koljonen et al.
BRITISH JOURNAL OF CANCER (2009)
Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients:: the AEIOU features
Michelle Heath et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Clonal integration of a polyomavirus in human Merkel cell carcinoma
Huichen Feng et al.
SCIENCE (2008)
Merkel cell carcinoma and HIV infection
EA Engels et al.
LANCET (2002)
Share Paper
